NHS to fund 'life changing' haemophilia drug
Emicizumab mimics the action of factor VIII to stem uncontrolled bleeds Related items fromOnMedica Child health should be election priority say experts and public Government launches its Child Health Strategy Cash-injection for sick children UK lagging behind other comparable countries on young people ’s health England falling behind on child health (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 21, 2019 Category: UK Health Source Type: news
'Trailblazing' treatment that prevents bleeds in haemophiliacs will be available on NHS England
Emicizumab, which mimics the missing protein, can be injected under the skin as little as every two weeks. It is now available after NHS England agreed to fund the drug, sold under the brand name Hemlibra. (Source: the Mail online | Health)
Source: the Mail online | Health - August 21, 2019 Category: Consumer Health News Source Type: news
New drug for people who can bleed uncontrollably
NHS England is funding a new treatment for patients with severe haemophilia A. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 21, 2019 Category: Consumer Health News Source Type: news
Life-changing drug to stop deadly bleeding available on the NHS
NHS England is to fund a life-changing treatment for thousands of people with severe haemophilia, which will dramatically cut their risk of life-threatening bleeds and reduce treatment time. (Source: NHS Networks)
Source: NHS Networks - August 20, 2019 Category: UK Health Source Type: news
Bayer recalls two lots of mislabeled hemophilia A med
The drugmaker is voluntarily recalling two lots that were filled with factor VIII hemophilia A treatment Jivi but were labeled as containing hemophilia treatment Kogenate FS (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 23, 2019 Category: Pharmaceuticals Source Type: news
Boy with bruises whose parents were 'accused of abusing him' diagnosed with a rare blood condition
Jack Fearns, of Cheshire, was six months old when his parents, Tom and Darryl-Anne Ferns, felt interrogated by doctors. Jack was diagnosed with haemophilia. (Source: the Mail online | Health)
Source: the Mail online | Health - July 19, 2019 Category: Consumer Health News Source Type: news
Dosing Differences Opined for Costly Hemophilia Option Dosing Differences Opined for Costly Hemophilia Option
Achieving the goal of zero bleeds as patients pursue active lives will require divergent dosing, according to PROPEL trial investigators who evaluated whether more exposure to FVIII improves outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 12, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Local biotechs UniQure, Casebia step up race for new hemophilia drugs
The race for new, long-lasting treatments for the two most common forms of hemophilia heated up this week as two local gene therapy companies presented trial data for drugs in development alongside Big Pharma players.
Lexington biotech UniQure N.V. (Nasdaq: QURE) — which has been the subject of M&A rumors in recent weeks, per Bloomberg — presented new data earlier this week on its treatment for hemophilia B, a form of the rare, genetic blood disease which affects the body’s ability to form… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 11, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news
BioMarin Appoints Pharmaceutical Veteran and Former J and J Executive, Liz McKee Anderson, to Board of Directors
SAN RAFAEL, Calif., July 9, 2019 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of pharmaceutical veteran and forme... Biopharmaceuticals, Personnel BioMarin Pharmaceutical, valoctocogene roxaparvovec, hemophilia A, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 9, 2019 Category: Pharmaceuticals Source Type: news
Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress
Roche today announced new data for Hemlibra ® (emicizumab) across multiple pivotal studies in people with haemophilia A with and without factor VIII inhibitors at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress on 6-10 July in Melbourne, Australia. (Source: Roche Media News)
Source: Roche Media News - July 9, 2019 Category: Pharmaceuticals Source Type: news
Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress
Roche today announced new data for Hemlibra ® (emicizumab) across multiple pivotal studies in people with haemophilia A with and without factor VIII inhibitors at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress on 6-10 July in Melbourne, Australia. (Source: Roche Investor Update)
Source: Roche Investor Update - July 9, 2019 Category: Pharmaceuticals Source Type: news
Contaminated blood scandal: Victims reveal 'coalition of secrecy'
Haemophiliac Alistair Bennett contracted HIV/Aids from a contaminated blood product. He died aged 22. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - July 2, 2019 Category: Consumer Health News Source Type: news
New plasma donation center takes space on Gadsden Highway
A new plasma donation center is set to open on July 10, at 222 Gadsden Highway in Birmingham.
OctaPharma is a Lachen, Switzerland-based company that allows people to donate plasma for medical production.
“OctaPharma converts donated plasma into plasma protein products used in more than 100 countries to treat life-threatening congenital and acquired diseases such as hemophilia A and B, immune deficiency syndromes, Rh disease in newborns and burn injuries,” Dr. David J. Aarons, medical director… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 18, 2019 Category: Biotechnology Authors: Tyler Patchen Source Type: news
Recombinant factor VIII-Fc good choice in haemophilia A
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 31, 2019 Category: Drugs & Pharmacology Source Type: news
BioMarin says data shows hemophilia gene therapy effects could wane
BioMarin Pharmaceutical Inc said on Tuesday early trial data for its gene therapy for hemophilia A suggested the one-time infusion's effect on some patients' bleeding disorders would last eight years. (Source: Reuters: Health)
Source: Reuters: Health - May 28, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
